<DOC>
	<DOCNO>NCT02800083</DOCNO>
	<brief_summary>- The study primary end point decrease number monthly heavy drinking day ( HDD ) ( ≥ 60 g/day men ≥ 40 g/d woman ) baseline end double blind Randomized Treatment ( RT ) . - The Secondary end point design assess safety tolerability investigate effect pitolisant alcohol use criterion ( e.g . total alcohol consumption , number abstinence day ) , crave well improvement mental health ( depression , sleep ) quality life . - Total alcohol consumption ( TAC ) baseline end treatment . TAC define mean daily alcohol consumption g/day month ( 28 day ) . - Percent patient without HDDs 24 week RT phase study . ( Continuous Controlled Drinking=CCD ) - Percent Abstinent Days RT phase ( PAD ) - Continuous Abstinence Duration baseline 24 week RT phase ( CAD ) - 4-week point prevalence abstinence end treatment - Improvement alcohol biomarkers ( e.g . ALAT , ASAT , % CDT ) 24 week RT phase - Craving ( Obsessive Compulsive Drinking Scale ) 24 week RT phase - Beck Depression Inventory ( BDI ) 24 week RT phase - Quality sleep ( Pittsburgh Sleep Quality Index ) RT phase . - Treatment retention 24 week RT - Quality life ( SF-12 ) RT phase - Percent patient without HDDs OL follow period - Quality life ( SF-12 ) OL phase - Quality sleep ( Pittsburgh Sleep Quality Index ) OL phase - Treatment retention OL phase Safety assess evaluation treatment emergent adverse event ( TEAE ) , physical examination , clinical laboratory test ( blood chemistry , hematology , urinalysis ) , subsequent end treatment potential withdrawal , evaluation scale physical examination , measurement heart rate , blood pressure , body weight study visit ) V0-FU5 ) . If ECG Fridericia 's correct QT interval ≥ 500 m difference baseline ≥ 60 m require check ECG second measurement lie 10 minute .</brief_summary>
	<brief_title>A Trial Evaluating Pitolisant ( BF2.649 ) Alcohol Use Disorder Treatment</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Alcohol-Induced Disorders , Nervous System</mesh_term>
	<criteria>Male female moderate severe DSM5 alcohol use disorder ( base alcohol use disorder section MINI Plus ) Ages 1865 . Low moderate alcohol withdrawal symptom : CIWAAr scale &lt; 10 baseline assessment Normal weight : 18 kg/m2 ≤ BMI ≤ 35 kg/m2 . Excessive alcohol use : number heavy drinking day ( ≥ 60 g/day men ≥ 40 g/d woman ) ≥15 30 day prior screen ≥7 2 week screen baseline . Treatmentseeking , treatment goal : reduce drinking abstinence If fertile , male female must agree use effective birth control . Females childbearing potential must use medically accepted effective method birth control , agree continue method duration study negative serum pregnancy test perform screen visit . Females breastfeed . Adequate social support accord investigator comply study requirement describe protocol ( e.g . transportation trial site , selfrating scale , drug compliance , schedule visit , etc. ) . Voluntarily express willingness participate study , understand protocol procedure sign date informed consent prior start protocol require procedure intoxicate ( BAC &lt; 0.05 ) . Willing receive psychosocial support History delirium tremens , epilepsy , withdrawal seizure Clinical depression suicidality : Beck Depression Inventory ( BDI ) &lt; 16 suicidality ( Item G =0 ) Recent illicit drug use , i.e . cannabis , cocaine , amphetamine opioids . Clinically significant cardiovascular , hematologic , severe hepatic impairment ( FLTs &gt; 3 ULN ) , renal ( Stage 2 3 accord international classification renal kidney disease ) , neurological , endocrinological abnormality abnormal clinical laboratory result ( case &gt; 3ULN ) . History serious head trauma injury cause loss consciousness last 3 minute . HIV positive ; HCV positive ; HBsAg positive History psychosis , current severe psychiatric disorder , e.g . schizophrenia , bipolar disorder , severe depression organic brain syndrome unrelated alcohol abuse Physical dependence sedative hypnotic require pharmacologically support detox . Receiving ongoing alcohol use disorder medication ( e.g . Baclofen ) Other active clinically significant illness , could interfere study conduct counterindicate study treatment place patient risk trial compromise study participation . Known history syncope , arrhythmia , myocardial infarction know significant ECG abnormality Known hypersensitivity test treatment include active substance excipients . Participation clinical trial receipt investigational drug ( ) previous 60 day , except explicitly approve Principal Investigator . Insufficient medical insurance accord local regulation . Pregnant woman pregnancy detect positive serum pregnancy test perform screen visit lactate woman Male subject want conceive child duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>